Sugi Predict

Sugi Predict / Compounds / SCHEMBL29617834

SCHEMBL29617834

SCHEMBL29617834

O=C(Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1F)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.60
▸ SLC29A1 Q99808 2/20 0.60
▸ TSHR P16473 2/20 0.60
▸ NFKB1 P19838 2/20 0.60
▸ THPO P40225 2/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ GLA P06280 1/20 0.60
▸ PMP22 Q01453 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ NPC1 O15118 1/20 0.60
▸ NPY1R P25929 1/20 0.60
▸ HTT P42858 1/20 0.60
▸ NPY2R P49146 1/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ RXFP1 Q9HBX9 1/20 0.60
▸ CYP1A2 P05177 1/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ ADORA1 P30542 7/20 0.59
▸ ADORA3 P0DMS8 4/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13975578 1.00 LMNA (0.60) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL314051 1.00 LMNA (0.60) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL9294393 1.00 LMNA (0.60) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL18521420 1.00 LMNA (0.60) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL314052 1.00 LMNA (0.60) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL23621389 1.00 LMNA (0.60) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL314050 1.00 LMNA (0.60) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL21063207 1.00 LMNA (0.60) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL21625242 1.00 LMNA (0.60) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL25748736 1.00 LMNA (0.60) LMNASLC29A1TSHRNFKB1THPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746905-A1 RSV VACCINE Astrazeneca AB (SE) 2026-05-27 — — EP disclosed
WO-2026104647-A1 VACCINE ASTRAZENECA AB (SE) 2026-05-21 — — WO disclosed
CN-122031506-A Chiral control 波涛生命科学有限公司 2026-05-15 — — CN disclosed
US-12583883-B2 Asymmetric auxiliary group WAVE LIFE SCIENCES LTD. (SG) 2026-03-24 — — US disclosed
WO-2025125630-A1 METHOD FOR BIOPROTAC DESIGN MEDIMMUNE LIMITED (GB) 2025-06-19 — — WO disclosed
EP-4522628-A2 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF Adarx Pharmaceuticals, Inc. (US) 2025-03-19 — — EP disclosed
US-20250041400-A1 RSV VACCINE ASTRAZENECA PHARMACEUTICALS LP 2025-02-06 — — US disclosed
CN-119351365-A N-deoxyribotransferase mutant and application thereof in synthesis of N6-Benzoyl-2 '-fluoro-2' -deoxyadenosine 上海合全药物研发有限公司 2025-01-24 — — CN disclosed
WO-2025017142-A1 RSV VACCINE ASTRAZENECA AB (SE) 2025-01-23 — — WO disclosed
US-20240229026-A1 CHIRAL CONTROL WAVE LIFE SCIENCES LTD. (SG) 2024-07-11 — — US disclosed
US-20240018180-A1 OLIGONUCLEOTIDE PRODUCTION METHOD AJINOMOTO CO., INC. (JP) 2024-01-18 — — US disclosed
EP-4293035-A1 OLIGONUCLEOTIDE PRODUCTION METHOD AJINOMOTO CO., INC. (JP) 2023-12-20 — — EP disclosed
WO-2023220737-A2 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF ADARX PHARMACEUTICALS, INC. (US) 2023-11-16 — — WO disclosed
EP-4219516-A2 CHIRAL CONTROL Wave Life Sciences Ltd. (SG) 2023-08-02 — — EP disclosed
CN-111263767-B Cyclic dinucleotides as stimulators of interferon gene modulators 北京轩义医药科技有限公司 2023-07-18 — — CN disclosed
US-11643657-B2 Chiral control WAVE LIFE SCIENCES LTD. (SG) 2023-05-09 — — US disclosed
EP-2872147-B1 METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES WAVE LIFE SCIENCES LTD (SG) 2022-12-21 — — EP disclosed
CN-109451740-B Cyclic dinucleotides for the treatment of disorders associated with STING activity, such as cancer 先天肿瘤免疫公司 2022-09-02 — — CN disclosed
US-20220127301-A1 ASYMMETRIC AUXILIARY GROUP WAVE LIFE SCIENCES JAPAN, INC. (JP) 2022-04-28 — — US disclosed
CN-108137641-B Cyclic dinucleotide compounds as sting agonists 默沙东公司 2022-04-01 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127301-A1 ASYMMETRIC AUXILIARY GROUP NIT2, IDH1, HBG2 LMNA 3240/4885SLC29A1 2141/4885TSHR 1995/4885
US-20240229026-A1 CHIRAL CONTROL RNGTT, POLI, NSUN3 LMNA 1868/4885SLC29A1 931/4885TSHR 3259/4885
US-12583883-B2 Asymmetric auxiliary group AGL, RNMT, NSUN2 LMNA 1824/4885SLC29A1 111/4885TSHR 3988/4885
US-11643657-B2 Chiral control RNGTT, POLI, NSUN3 LMNA 1868/4885SLC29A1 931/4885TSHR 3259/4885
US-20250041400-A1 RSV VACCINE LSS, SLFN12, FDPS LMNA 213/4885SLC29A1 3827/4885TSHR 4097/4885
US-20240018180-A1 OLIGONUCLEOTIDE PRODUCTION METHOD RNGTT, NOX4, POLRMT LMNA 4781/4885SLC29A1 2562/4885TSHR 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.